The DOI matches its Crossref record.
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
Open accessAbstract
BACKGROUND: The investigation of angiogenesis inhibitors is of particular interest in renal cell carcinoma (RCC), in which dysregulated blood vessel formation has been correlated with shortened survival. Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor. We conducted this study to (a) determine if sorafenib is anti-angiogenic, and (b) to relate anti-angiogenic effect to outcome. RESULTS: Four patients achieved partial response by WHO criteria (ORR 24%). Median time to progression (TTP) was 12.9 months. K(trans) decreased significantly during treatment with sorafenib (60.3% decline, 95% CI 46.1-74.6%). The percent decline in K(trans) and change in tumor size by CT scan were significantly associated with progression-free survival (p = 0.01 and 0.05, respectively). In addition, K(trans) at baseline was also significantly associated with progress-free survival (p = 0.02). PATIENTS AND METHODS: Seventeen patients with metastatic RCC underwent dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI). DCE-MRI was used to calculate the gadolinium exchange constant between blood and tumor interstitial tissue, K(trans). CONCLUSIONS: In patients with RCC, inhibition of tumor vascular permeability by sorafenib was associated with improved outcome. Moreover, baseline tumor vascular permeability, expected to be a poor prognosis factor, was a predictive marker of favorable response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics
Ferretti, S., Allegrini, P. R., Becquet, M. M., & McSheehy, P. M. J. (2009) · Neoplasia · doi:10.1593/neo.09554 · Cited by 106
Metadata
- Authors
- Flaherty, K. T., A. Rosen, M., F. Heitjan, D., L. Gallagher, M., Schwartz, B., D. Schnall, M., & O'Dwyer, P. J.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2008-04
- Volume
- 7
- Issue
- 4
- Pages
- 496-501
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W1972528770
- Cited by
- 193
- References
- 0
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. https://app.cochat.ai/papers/10.4161/cbt.7.4.5624
- The paper
- Flaherty, K. T., A. Rosen, M., F. Heitjan, D., L. Gallagher, M., Schwartz, B., D. Schnall, M., & O'Dwyer, P. J. (2008). Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biology & Therapy. https://doi.org/10.4161/cbt.7.4.5624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.